Roka Goes Public in $60M Stock Offering | GenomeWeb

NEW YORK (GenomeWeb) – Roka Bioscience today priced its initial public offering of 5 million shares at $12 per share, raising gross proceeds of $60 million.

The Warren, NJ-based firm, which makes molecular diagnostic tests for foodborne pathogens, will begin trading today on the Nasdaq Global Market under the ticker symbol "ROKA". The share price is below the previously anticipated range of $14 to $16 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.